Quantum Dot Physics vs. Classical Fluorophores
Quantum dots are semiconductor nanocrystals (2–10 nm diameter) whose optical properties arise from quantum confinement effects. Unlike organic fluorophores with fixed absorption/emission profiles, QD emission wavelength is tunable by particle size: CdSe core of 2.3 nm emits at 510 nm (green); 5.2 nm emits at 620 nm (red). Full-width at half-maximum (FWHM) of 12–18 nm vs. 40–60 nm for organic dyes enables tight multiplexing without spectral deconvolution algorithms. A single 405 nm excitation source drives all QD sizes simultaneously — simplifying the optical reader architecture. Molar extinction coefficients are 10–100× higher than organic dyes, contributing to the SNR advantage.
Bioconjugation Strategy & Surface Chemistry
COOH-functionalised QDs (CdSe/ZnS, Thermo Fisher Qdot™) were conjugated to anti-CRP, anti-PCT, anti-cTnI, anti-IL-6, anti-BNP, and anti-D-dimer monoclonal antibodies via EDC/NHS coupling chemistry. Conjugation efficiency was assessed by size-exclusion chromatography (SEC): 2.8±0.4 antibody molecules per QD. Non-specific binding was suppressed using PEG(2000)-COOH backfill — reducing NSB from 8.2% to 1.1% of total signal vs. non-PEGylated constructs. ZnS shell thickness (3 monolayers) was critical for stability: thinner shells showed 40% quantum yield reduction at pH 5.5 encountered in whole blood matrices.
6-Plex Detection Performance
The 6-plex assay (CRP, PCT, cTnI, IL-6, BNP, D-dimer) was run simultaneously on 3mm × 10mm nitrocellulose membranes. Emission spectra were collected at 515, 545, 565, 590, 620, and 655 nm using a custom 6-channel fluorescence reader with 5nm bandpass filters. Limit of detection: CRP 0.08 mg/L, PCT 0.04 µg/L, cTnI 0.9 pg/mL, IL-6 0.6 pg/mL, BNP 8.1 pg/mL, D-dimer 38 ng/mL FEU — all meeting or exceeding WHO clinical decision thresholds. Cross-reactivity between channels <0.8% at analyte concentrations 10× LoD.
Regulatory & Stability Considerations for QD Reagents
CdSe QDs contain cadmium — classified as an EU REACH SVHC (Substance of Very High Concern). Biocompatibility assessment per ISO 10993-17 risk characterisation: calculated systemic cadmium dose at maximum device use = 0.0003 µg/kg/day — 4,000× below ECHA's oral DNEL of 0.36 µg/kg/day for non-occupational exposure. Shelf-life data: QD-antibody conjugates retain >95% immunoreactivity after 18 months at 4°C in 0.1M sodium borate pH 8.3 with 0.1% BSA stabiliser. InP/ZnSe (cadmium-free) QDs evaluated as a regulatory-preferred alternative — currently showing 3.1× SNR improvement vs. FITC, pending further optimisation.